US panel backs trendy peptides despite safety concerns
Sign up now: Get ST's newsletters delivered to your inbox
Peptide proponents offer sweeping claims about their benefits, ranging from glowing skin and muscle growth to brain health and wound healing.
PHOTO: REUTERS
- A US panel recommended allowing specialised pharmacies to produce four trendy peptides despite safety and efficacy concerns raised by medical experts.
- The peptides, popular in wellness circles but lacking strong clinical evidence, include BPC-157, KPV, TB-500, and MOT-c.
- Critics warn the decision favours commercial interests over science and could pose risks, while supporters argue it promotes medical freedom and reduces grey market use.
AI generated
NEW YORK – A US review panel on July 23 recommended loosening restrictions on multiple trendy peptides, endorsing proposals that specialised pharmacies be allowed to produce such substances despite alarm bells from medical experts over safety concerns.
The vote came as part of a two-day meeting of the panel tasked with considering whether seven total peptides should be added to the approved compounding list, which allows facilities to create custom drugs that will in turn be more accessible to the public.
By the end of the marathon meeting, the panel had greenlit recommendations allowing bespoke pharmacies to produce four peptides: BPC-157, KPV, TB-500 and MOT-c.
They will consider three more substances on July 24.
The panel recommendations are not binding, but the Food and Drug Administration (FDA) has historically given them significant weight.
The positive votes are a rebuke to the agency’s career scientists who urged maintaining restrictions over the lack of data and safety concerns.
Peptides are short chains of amino acids, which are the building blocks of proteins. They occur naturally in the body, but synthetic peptides are increasingly buzzy in the wellness industry as the key to an optimised life.
Proponents offer sweeping claims about their benefits, ranging from glowing skin and muscle growth to brain health and wound healing.
There is scant to no clinical evidence supporting such promises.
Medical experts accused US President Donald Trump’s health chief Robert F. Kennedy Jr of packing the FDA advisory committee with people who have strong ties to the peptide industry, given his personal interest in and use of the products.
The substances under review are among those that former president Joe Biden’s administration restricted from compounding, notably because of a lack of human clinical trial data.
But they are still popular. Peptides are available online from chemical suppliers “for lab use”.
They are widely touted on social media among influencers, celebrities and those inclined to follow “wellness” trends, such as Kennedy.
Proponents of legal access to peptides, including Kennedy, argue that restricting them only drives Americans deeper into the grey market.
Panel member Elizabeth Rebello, a pharmacist and anesthesiologist, told the committee that she voted no on BPC-157 “because of the lack of efficacy data” and “safety concerns”.
Member Brian Lee also voted against that peptide, saying: “I think this endorsement can be potentially harmful, and I cannot in good conscience vote yes.”
But they were outnumbered by panellists who voted in favour, with those members citing reasons such as “the greater good” and “medical freedom” for their decisions.
‘Weak evidence’ versus commercial benefit
Panellists heard presentations by FDA scientists who warned against recommending expanded access, as well as public comment.
Peter Lurie, president of the Center for Science in the Public Interest and a former FDA official, urged against easing restrictions on the peptides, calling such an action “inconsistent” with FDA standards and dangerous to consumers.
He dubbed the burgeoning world of peptides as one of “pseudoscience and grift”.
Lurie told AFP: “What I think we’re seeing is the demise of the advisory committee as a useful instrument in scientific decision-making under this administration.
“They stacked the committee with a group of people who, in the face of extremely weak evidence, voted in favour of these products anyway, and the FDA’s efforts to balance that out weren’t sufficient.”
A representative for telehealth company Hims and Hers noted that the company would “benefit commercially” if it were allowed to offer peptides such as BPC-157.
“I’m not going to tell you that the evidence for BPC-157 is strong. It isn’t, and I won’t overclaim,” said Anant Vinjamoori, the chief medical officer of the online medication provider’s Hims branch.
“What I’d ask is that you not read thin as non-existent.”
Should the peptides ultimately be added to the bulks list for compounding, that does not mean they are FDA-approved. The bulks list rather dictates what ingredients compounding pharmacies can use when mixing custom medications for patients with a specific prescription. AFP
